Deirdre J Cohen
Affiliation: New York University School of Medicine
- Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibitionDeirdre J Cohen
Division of GI Oncology, NYU Cancer Institute, 160 East 34th Street, New York, NY 10016, USA
Hematol Oncol Clin North Am 26:565-88, viii. 2012..This article summarizes the mechanism of Hh pathway signal transduction, discusses the models of pathway activation, reviews the clinical data using Hh inhibitors, and discusses challenges to the development of pathway inhibitors...
- An expert opinion on esophageal cancer therapyDeirdre J Cohen
NYU Langone Medical Center, Division of Medical Oncology, New York University Cancer Institute, 160 East 34th Street, New York, NY 10016, USA
Expert Opin Pharmacother 12:225-39. 2011..Most patients present with regional or distant disease and, therefore, have a very poor prognosis...
- Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinomaDeirdre J Cohen
Division of Medical Oncology, New York University Cancer Center, NYU Medical Center, New York, NY, USA
Ann Surg Oncol 19:478-85. 2012..However, locoregional recurrences remain high. Accordingly, we instituted this pilot/feasibility study, including intraperitoneal 5-fluoro-2'-deoxyuridine (IP FUDR) as part of the treatment...
- Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancerStacey Stein
NYU Cancer Institute and Department of Medicine, New York University School of Medicine, NY, USA
Clin Colorectal Cancer 9:S44-50. 2010....
- Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancerDeirdre J Cohen
Department of Medicine, NYU Clinical Cancer Center, New York, NY 10016, USA
Clin Colorectal Cancer 7:S21-7. 2007....
- Rationale for combining biotherapy in the treatment of advanced colon cancerDeirdre J Cohen
Department of Medicine Clinical, Pharmacology, New York University, Cancer Institute, New York, NY
Gastrointest Cancer Res 2:145-51. 2008..We review the various molecular targets of biologic therapy in colon cancer, discuss the rationale for their use as single agents and in combination, and present clinical evidence demonstrating their efficacy...